Janssen's Erdafitinib 'significantly extended' survival of FGFR2/3-altered urothelial cancer 08-Jun-2023 By Liza Laws The Janssen Pharmaceutical Companies of Johnson & Johnson announced its drug Erdafitinib extends survival in bladder cancer.
Site-selection for laser-based bladder cancer study led by trial management organization 25-Jul-2019 By Maggie Lynch Theralase taps an undisclosed trial management organization for the site selection of its multi-country bladder cancer study which aims to enroll 100 patients across 20 sites.